Fenofibrate lowers lipid content in the bloodstream; it also directly inhibits glycolysis in glioma cells by disrupting binding of the NF-κB-HIF1a complex to the PKM2 promoter (Han D. et al., 2015). Here, NFKB1 is linked to central nervous system cancer.